Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 2 » Issue 3

Religiosity in patients with Parkinson's disease

Authors Patrick McNamara, Raymon Durso, Ariel Brown

Published Date October 2006 Volume 2006:2(3) Pages 341—348

DOI

Published 10 October 2006

Patrick McNamara, Raymon Durso, Ariel Brown

Department of Neurology, Boston University School of Medicine, Boston, MA, and VA Boston Healthcare System, Boston, MA, USA

Objective: To study clinical correlates of religiosity in Parkinson’s disease (PD).

Methods: Measures of life goals, religiosity, mood, and neuropsychologic function were assessed in 22 persons with mid-stage PD and 20 age-matched healthy controls. Levodopa dose equivalents (LDE) were also computed for the patients.

Results: Relative to other major life goals parkinsonian patients were significantly more likely to report that “my religion or life philosophy” was less important than were age-matched controls. Scores on a battery of religiosity scales were consistently lower for Parkinson’s patients than those of age-matched controls. While Mini Mental State Exam, logical memory recall, Stroop, and selected (depression and anxiety) mood scales reliably distinguished patients from controls, only measures of prefrontal function correlated with religiosity scores.

Conclusions: Patients with PD express less interest in religion and report consistently lower scores on measures of religiosity than age-matched controls. Prefrontal dopaminergic networks may support motivational aspects of religiosity.

Keywords: religiosity, Parkinson’s disease, neuropsychology, mood, executive functions, dopamine agonists

Download Article [PDF] 

Readers of this article also read:

Femtosecond laser versus mechanical microkeratome-assisted flap creation for LASIK: a prospective, randomized, paired-eye study

Pajic B, Vastardis I, Pajic-Eggspuehler B, Gatzioufas Z, Hafezi F

Clinical Ophthalmology 2014, 8:1883-1889

Published Date: 22 September 2014

Linear polyethylenimine produced by partial acid hydrolysis of poly(2-ethyl-2-oxazoline) for DNA and siRNA delivery in vitro

Fernandes JC, Qiu X, Winnik FM, Benderdour M, Zhang X, Dai K, Shi Q

International Journal of Nanomedicine 2013, 8:4091-4102

Published Date: 31 October 2013

Physical performance in recently aged adults after 6 weeks traditional Thai dance: a randomized controlled trial

Janyacharoen T, Laophosri M, Kanpittaya J, Auvichayapat P, Sawanyawisuth K

Clinical Interventions in Aging 2013, 8:855-859

Published Date: 24 July 2013

Subconjunctival hemorrhage: risk factors and potential indicators

Tarlan B, Kiratli H

Clinical Ophthalmology 2013, 7:1163-1170

Published Date: 12 June 2013

Novel nanostructured biomaterials: implications for coronary stent thrombosis

Karagkiozaki V, Karagiannidis PG, Kalfagiannis N, Kavatzikidou P, Patsalas P, Georgiou D, Logothetidis S

International Journal of Nanomedicine 2012, 7:6063-6076

Published Date: 17 December 2012

A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations

Karavana SY, Gökçe EH, Rençber S, Özbal S, Pekçetin Ç, Güneri P, Ertan G

International Journal of Nanomedicine 2012, 7:5693-5704

Published Date: 9 November 2012

The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy

Sterjev Z, Trencevska GK, Cvetkovska E, Petrov I, Kuzmanovski I, Ribarska JT, Nestorovska AK, Matevska N, Naumovska Z, Jolevska-Trajkovic S, Dimovski A, Suturkova L

Neuropsychiatric Disease and Treatment 2012, 8:191-196

Published Date: 19 April 2012

Nanomedicines in renal transplant rejection – focus on sirolimus

Li-Jiuan Shen, Fe-Lin Lin Wu

International Journal of Nanomedicine 2007, 2:25-32

Published Date: 25 October 2007